Stay updated on CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab
Sign up to get notified when there's something new on the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page.

Latest updates to the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page
- Check2 days agoChange DetectedThe study page displays a 403 Forbidden error instead of the study record content, replacing the expected information with an error screen and navigation footer.SummaryDifference21%

- Check9 days agoChange DetectedA prompt to locate contact information was added to the page, improving accessibility for inquiries about the study. The page revision was updated to v3.7.0, reflecting an updated version of the content.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page now lists Revision: v3.6.6, replacing v3.6.5, indicating a maintenance release of the site. It reflects an update to the site's version tag rather than any changes to study data or user-facing content.SummaryDifference0.0%

- Check44 days agoChange DetectedThe page shows a new Revision: v3.6.5, replacing the previous v3.6.4. This reflects a minor backend/version update and does not change the study information or how the page is used.SummaryDifference0.0%

- Check66 days agoChange DetectedSite revision updated from v3.6.3 to v3.6.4, signaling a platform update rather than any modification to the study details.SummaryDifference0.0%

- Check73 days agoChange DetectedPublications section added with a PubMed-derived citation and a note about automatic population from PubMed. The change provides direct literature references and clarifies data provenance for the study record.SummaryDifference0.2%

Stay in the know with updates to CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab
Enter your email address, and we'll notify you when there's something new on the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page.